

## SUBJECT INDEX

- Active avoidance reflex extinction, 515  
 adrenocorticotrophic hormone  
 receptor blockers
- Acute administration, 699  
 ammonium chloride  
 creatinine  
 thermoregulatory responses  
 urea
- Acute exposure, 265  
 analgesia  
 chronic exposure  
 nicotine  
 restraint stress  
 tolerance development
- Acute treatment, 541  
 anxiety  
 avoidance acquisition  
 benzodiazepines  
 chronic treatment  
 handling habituation
- Adrenergic receptor antagonists, 573  
 lordosis  
 luteinizing hormone-releasing hormone  
 sexual experience
- $\alpha_2$ -Adrenoceptors, 33  
 chronic stress  
 clonidine  
 naltrexone
- $\beta$ -Adrenoceptors, 807  
 experimental diabetes  
 tricyclics
- Adrenocorticotrophic hormone, 515  
 active avoidance reflex extinction  
 receptor blockers
- Aggression  
 analgesia, 43  
 cats, 791  
 feeding, 43  
 locomotor activity, 43  
 mice, male, 43  
 midbrain periaqueductal grey, 791  
 naloxone, 791  
 opiate agonists, 43  
 opiate antagonists, 43
- Aggression, shock-induced, 103  
 animal depression model  
 clomipramine  
 neonatal administration
- Aging  
 cortex, 505  
 hamsters, 885  
 hippocampus, 885  
 hypoactivity, 885  
 obesity, 885  
 passive-avoidance response, 611  
 [ $^3$ H]-prazosin binding, 505  
 serotonin, 885  
 temazepam, 611
- Alcohol, 649  
 behavioral effects  
 comparison profiles  
 marijuana  
 subjective effects
- Alcohol intake, 813  
 angiotensin II  
 Sar-1 Thr-8 angiotensin II
- Alcohol preferring/alcohol-nonpreferring  
 rat comparisons, 215  
 ethanol  
 ethanol aversion
- Alpha noradrenergic agonists, 87  
 catalepsy
- Aluminum, 467  
 chronic administration  
 oral administration  
 passive avoidance
- Amfonelic acid, 623  
 cocaine  
 intravenous self-administration
- $\gamma$ -Aminobutyric acid, 411  
 caudate spindle  
 drug comparisons  
 taurine
- $\gamma$ -Aminobutyric acid antagonists, 657  
 lumbosacral injection  
 penile reflexes  
 rats, male  
 sexual behavior
- Aminoxyacetic acid, 693  
 anticonflict effects  
 diazepam  
 pentobarbital  
 phenobarbital
- Ammonium chloride, 699  
 acute administration  
 creatinine  
 thermoregulatory responses  
 urea
- Amnesia, 405  
 cholinergic neuronal system  
 cycloheximide  
 GABAergic neuronal system
- Amniotic fluid, 351  
 analgesia  
 dose-dependent effects  
 morphine  
 placenta  
 tail-flick latency
- Amphetamine  
 circling behavior, 705  
 housing, 59  
 intravenous self-administration, 59  
 sensitization, 705
- d-Amphetamine  
 atypical antipsychotics, 519  
 baboons, 585  
 BALB/cByJ mice, 675  
 chronic administration, 675  
 concurrent schedule, 227  
 fenfluramine, 585
- food intake, 585  
 locomotor activity, 675  
 methylphenidate, 675  
 monetary reinforcement, 227  
 social interaction, 227  
 stereotypy, 519  
 time allocation, 227
- Analgesia  
 acute exposure, 265  
 aggression, 43  
 amniotic fluid, 351  
 anesthesia, 397  
 chronic exposure, 265  
 cold water swim, 27  
 differential effects, 27, 397  
 dose-dependent effects, 351  
 feeding, 43  
 formalin test, 855  
 5-hydroxytryptamine, 855  
 intrathecal administration, 27  
 locomotor activity, 43  
 methysergide, 27  
 mice, male, 43  
 morphine, 351, 855  
 nicotine, 265  
 opiate agonists, 43  
 opiate antagonists, 43  
 opiates, 397  
 phenolamine, 27  
 placenta, 351  
 restraint stress, 265  
 tail flick latency, 351, 397  
 tolerance development, 265
- Anesthesia, 397  
 analgesia  
 differential effects  
 opiates  
 tail flick latency
- Anesthetic effects, 453  
 anticonvulsant effects  
 flurazepam  
 hypothermic effects  
 selective breeding
- Angiotensin II  
 alcohol intake, 813  
 drinking, 493  
 intracranial injections, 493  
 Sar-1 Thr-8 angiotensin II, 813  
 tachykinins, 493
- Animal depression model, 103  
 aggression, shock-induced  
 clomipramine  
 neonatal administration
- Anorexia, 209  
 carbachol  
 feeding  
 hypothalamus  
 norepinephrine  
 rats, tumor-bearing
- Anorexia cachexia, 69

- domperidone
- gastric ulceration
- pimozide
- Anticonflict effects, 693
  - aminooxyacetic acid
  - diazepam
  - pentobarbital
  - phenobarbital
- Anticonvulsant effects
  - anesthetic effects, 453
  - benzodiazepine/GABA receptor complex, 751
  - ethanol, 751
  - flurazepam, 453
  - hypothermic effects, 453
  - RO 15-4513, 751
  - selective breeding, 453
- Anticonvulsants, 153
  - barrel rotation
  - intrastratial injection
  - quinolinic acid
- Antidepressant drugs, 243
  - intracranial self-administration
  - long-term administration
- Antihistamines, 81
  - feeding behavior
- Antinociception
  - p-chloroamphetamine, 135
  - drug interactions, 641
  - ketanserin, 641
  - morphine, 641
  - pirenperone, 641
  - serotonergic pathways, 135
  - tail-flick latency, 641
- Antiserotonergic properties, 321
  - yohimbine
- Anxiety
  - acute treatment, 541
  - avoidance acquisition, 541
  - benzodiazepine receptor ligands, 761
  - benzodiazepines, 541
  - bupirone, 317
  - chlordiazepoxide, 313
  - chronic treatment, 541
  - dopamine transmitters, 317
  - drug interactions, 761
  - ethanol, 761
  - exploration, 761
  - fluid consumption, 313
  - handling habituation, 541
  - locomotor activity, 761
  - neophobia, 313
  - stress ulcer, 317
- Anxiolytic activity, 959
  - thigmotaxis
- Apomorphine
  - conditioned avoidance, 291
  - domperidone, 201
  - drug comparisons, 201
  - ethanol, 163
  - genital grooming, 717
  - haloperidol, 201
  - hypomotility, 291
  - intermittent administration, 871
  - locomotor activity, 871
  - luteinizing hormone releasing hormone, 291, 871
  - motility, 163
  - penile reflexes, 201
  - spontaneous motor activity, 291
  - stereotypy, 871
  - withdrawal, 163
  - yawning, 717
- Apparatus
  - mini-osmotic pumps, 627, 633
  - Morris swim maze, 141
  - radial arm maze, 467
- Atropine, 381
  - cardiac response
  - monkeys
  - parasympathetic activity
  - pyridostigmine
- Attenuation, 909
  - conditioned taste aversion
  - cross-attenuation
  - ethanol
  - ionizing radiation
  - lithium chloride
- Atypical antipsychotics, 519
  - d-amphetamine
  - stereotypy
- Aversion, 193
  - GABAergic blockade
  - medial hypothalamus
  - morphine
  - periaqueductal gray
- Avoidance, 337
  - BM123
  - spontaneous alternation
- Avoidance acquisition, 541
  - acute treatment
  - anxiety
  - benzodiazepines
  - chronic treatment
  - handling habituation
- Baboons, 585
  - d-amphetamine
  - fenfluramine
  - food intake
- BALB/cByJ mice, 675
  - d-amphetamine
  - chronic administration
  - locomotor activity
  - methylphenidate
- Barbital, 179
  - chronic treatment
  - cross-tolerance
  - ethanol
  - pentobarbital
- Barrel rotation, 153
  - anticonvulsants
  - intrastratial injection
  - quinolinic acid
- Behavioral activation, 255
  - dopamine
  - neurokinin- $\alpha$
  - ventral tegmental area
- Behavioral dependence, 927
  - caffeine
  - interactive effects
  - monkeys
  - phencyclidine
- Behavioral effects, 649
  - alcohol
  - comparison profiles
  - human studies
  - marijuana
  - subjective effects
- Behavioral investigation, 9
  - methamphetamine
  - PMMA
- Benzodiazepine/GABA receptor complex, 751
  - anticonvulsant effects
  - ethanol
    - RO 15-4513
- Benzodiazepine receptor
  - CGS 9896, 249
  - drug discrimination, 249
  - drug interactions, 733
  - ethanol, 733
  - partial inverse agonist, 733
  - RO 15-4513, 733
  - stimulus antagonism, 249
- Benzodiazepine receptor ligands, 761
  - anxiety
  - drug interactions
  - ethanol
  - exploration
  - locomotor activity
- Benzodiazepine responsiveness, 15
  - cholinergic function
- Benzodiazepines, 541
  - acute treatment
  - anxiety
  - avoidance acquisition
  - chronic treatment
  - handling habituation
- Blood pressure, 387
  - cardiovascular activity
  - cocaine
  - human studies
  - task performance
- BM123, 337
  - avoidance
  - spontaneous alternation
- Body weight, 533
  - doves
  - food intake
  - growth hormone
  - prolactin
  - sex differences
- Brain
  - amygdala, 825
  - caudate-putamen, 523
  - cerebral cortex, 839
  - cingulate cortex, 523, 845
  - dentate gyrus, 523
  - dorsal tegmentum, 547
  - dorsomedial hypothalamus, 825
  - entorhinal-subicular cortex, 523
  - frontal cortex, 499
  - hippocampus, 15, 885
  - hypothalamus, 209, 523
  - lateral hypothalamus, 547, 825, 845
  - lateral ventricle, 169, 175
  - medial hypothalamus, 193
  - midbrain periaqueductal grey, 791
  - midbrain pons, 547
  - nucleus basalis magnocellularis, 141
  - paraventricular hypothalamus, 825
  - periaqueductal gray, 193
  - preoptic area, 169, 175
  - preoptic-diagonal band, 523
  - septum, 825
  - striatum, 15
  - thalamus, 523
  - ventral tegmental area, 255
  - ventral tegmentum, 547
- Brain development, 839
  - offspring effects
  - prenatal stress
  - serotonergic system
- Brainstem, 547
  - cholinergic antagonists
  - lateral hypothalamus
  - self-stimulation

- ventral tegmentum
- Buspirone
  - anxiety, 317
  - m-chlorophenylpiperazine, 567
  - dopamine transmitters, 317
  - food intake, 567
  - gepirone, 269
  - locomotor activity, 567
  - 8-OH-DPAT, 567
  - rats, wild, 269
  - strain differences, 567
  - stress ulcer, 317
  - taming, 269
- Caffeine
  - behavioral dependence, 927
  - conditioned taste aversion, 579
  - drug conditioning, 579
  - interactive effects, 927
  - monkeys, 927
  - phencyclidine, 927
- Cannula-mapping, 825
  - eating
  - opioid agonists
- Carbachol
  - anorexia, 209
  - feeding, 209
  - hypothalamus, 209
  - lateral ventricle, 169
  - norepinephrine, 209
  - oxotremorine, 169
  - preoptic area, 169
  - rats, experienced males, 169
  - rats, tumor-bearing, 209
  - sexual behavior, 169
- Carbohydrate, 773
  - fat intake
  - d-fenfluramine
  - hyperphagia, diet-induced
  - serotonin
- Carbon monoxide, 93
  - cigarettes
  - human studies, smokers
- Cardiac response, 381
  - atropine
  - monkeys
  - parasympathetic activity
  - pyridostigmine
- Cardiovascular activity, 387
  - blood pressure
  - cocaine
  - human studies
  - task performance
- Cardiovascular effects, 877
  - cocaine
  - drug interactions
  - ethanol
  - human studies, males
- Catalepsy, 87
  - alpha noradrenergic agonists
- Cats
  - aggression, 791
  - cholecystokinin, 297
  - food intake, 297
  - midbrain periaqueductal grey, 791
  - naloxone, 791
  - structure-activity relationship, 297
- Caudate spindle
  - $\gamma$ -aminobutyric acid, 411
  - dopamine receptors, 417
  - drug comparisons, 411
  - lesions, 6-hydroxydopamine, 417
- taurine, 411, 417
- Cerebral metabolism, 481
  - 2-deoxyglucose
  - naloxone
  - opioid antagonists
- CGS 8216, 375
  - drug interactions
  - ethanol
  - Ro 15-1788
  - Ro 15-4513
  - schedule-controlled responding
- CGS 9896, 249
  - benzodiazepine receptor
  - drug discrimination
  - stimulus antagonism
- Charybdotoxin, 187
  - motor recovery
  - spinal cord injury
- Chloramphenicol, 933
  - morphine
  - self-stimulation
- Chlordiazepoxide
  - anxiety, 313
  - fluid consumption, 313
  - locomotor activity, 371
  - naloxone, 371
  - neophobia, 313
  - opioid mechanisms, 371
- p-Chloroamphetamine, 135
  - antinociception
  - serotonergic pathways
- m-Chlorophenylpiperazine, 567
  - buspirone
  - food intake
  - locomotor activity
  - 8-OH-DPAT
  - strain differences
- Cholecystokinin, 297
  - cats
  - food intake
  - structure-activity relationship
- Cholesterol, 75
  - cingulotomy
  - corticosterone
  - $\beta$ -endorphin
  - plasma
  - stress
  - triglycerides
- Cholinergic antagonists, 547
  - brainstem
  - lateral hypothalamus
  - self-stimulation
  - ventral tegmentum
- Cholinergic function
  - benzodiazepine responsiveness, 15
  - selective breeding, 345
  - serotonergic sensitivity, 345
- Cholinergic neuronal system, 405
  - amnesia
  - cycloheximide
  - GABAergic neural system
- Chronic administration
  - aluminum, 467
  - d-amphetamine, 675
  - BALB/cByJ mice, 675
  - locomotor activity, 675
  - methylphenidate, 675
  - oral administration, 467
  - passive avoidance, 467
  - pentobarbital, 459
  - pigeon/rat comparisons, 459
  - secobarbital, 459
  - tolerance, 459
- Chronic exposure, 265
  - acute exposure
  - analgesia
  - nicotine
  - restraint stress
  - tolerance development
- Chronic stress, 33
  - $\alpha_2$ -adrenoceptors
  - clonidine
  - naltrexone
- Chronic treatment
  - acute treatment, 541
  - anxiety, 541
  - avoidance acquisition, 541
  - barbital, 179
  - benzodiazepines, 541
  - cross-tolerance, 179
  - ethanol, 179
  - handling habituation, 541
  - pentobarbital, 179
- Cigarettes, 93
  - carbon monoxide
  - human studies, smokers
- Cimetidine, 107
  - cold-water swims
  - nonopioid analgesia
  - opioid analgesia
- Cingulotomy, 75
  - cholesterol
  - corticosterone
  - $\beta$ -endorphin
  - plasma
  - stress
  - triglycerides
- Circling behavior, 705
  - amphetamine
  - sensitization
- Classical conditioning, 605
  - drug addiction model
  - lesions, 6-hydroxydopamine
  - rotational behavior
- Clomipramine, 103
  - aggression, shock-induced
  - animal depression model
  - neonatal administration
- Clonidine, 33
  - $\alpha_2$ -adrenoceptors
  - chronic stress
  - naltrexone
- Cocaine
  - amfonelic acid, 623
  - blood pressure, 387
  - cardiovascular activity, 387
  - cardiovascular effects, 877
  - computer simulation, 327
  - dopamine uptake/release, 327
  - drug interactions, 355, 877
  - ethanol, 877
  - human studies, 387
  - human studies, males, 877
  - intravenous self-administration, 623
  - in vivo, 327
  - task performance, 387
- Cold water swim
  - analgesia, 27
  - cimetidine, 107
  - differential effects, 27
  - intrathecal administration, 27
  - methysergide, 27
  - nonopioid analgesia, 107
  - opioid analgesia, 107
  - phentolamine, 27
- Comparison profiles, 649

- alcohol
  - behavioral effects
  - human studies
  - marijuana
  - subjective effects
- Computer simulation, 327
- cocaine
  - dopamine uptake/release
  - in vivo
- Concurrent schedule, 227
- d-amphetamine
- monetary reinforcement
- social interaction
- time allocation
- Conditioned avoidance, 291
  - apomorphine
  - hypomotility
  - luteinizing hormone releasing hormone
  - spontaneous motor activity
- Conditioned Emotional Response, 949
  - ethanol
    - ethanol intake
    - sucrose-fading procedure
- Conditioned place preference, 1
  - conditioned taste aversion
  - dopamine agonists
  - opposing effects
- Conditioned taste aversion
  - attenuation, 909
  - caffeine, 579
  - conditioned place preference, 1
  - cross-attenuation, 909
  - dopamine agonists, 1
  - drug conditioning, 579
  - ethanol, 909
  - ionizing radiation, 909
  - lithium chloride, 909
  - opposing effects, 1
- Conflict test, 757
  - ethanol
    - reaction time
    - RO 15-4513
- Continuous administration
  - physostigmine, 627, 633
  - scopolamine, 633
  - soman, 633
  - soman activity, 633
  - toxicity study, 633
- Cortex, 505
  - aging
    - [<sup>3</sup>H]-prazosin binding
- Corticosterone, 75
  - cholesterol
  - cingulotomy
  - $\beta$ -endorphin
  - plasma
  - stress
  - triglycerides
- Creatinine, 699
  - acute administration
  - ammonium chloride
  - thermoregulatory responses
  - urea
- Cross-attenuation, 909
  - attenuation
  - conditioned taste aversion
  - ethanol
  - ionizing radiation
  - lithium chloride
- Cross-tolerance, 179
  - barbital
  - chronic treatment
- ethanol
  - pentobarbital
- Current intensity, 845
  - performance
  - pimozide
  - reward
  - self-stimulation
- Cycloheximide, 405
  - amnesia
  - cholinergic neuronal system
  - GABAergic neuronal system
- Delayed matching-to-sample, 953
  - differential effects
  - neuroleptics
  - pigeons
- 2-Deoxyglucose, 481
  - cerebral metabolism
  - naloxone
  - opioid antagonists
- [D-Arg<sup>2</sup>]-Dermorphin, 439
  - drug/peptide comparisons
  - morphine
  - route of administration
- Diazepam
  - aminooxyacetic acid, 693
  - anticonflict effects, 693
  - drug interactions, 597
  - ethanol, 597
  - instrumental behaviors, 597
  - pentobarbital, 597, 693
  - phenobarbital, 693
  - Ro 15-1788, 597
  - Ro 15-4513, 597
- Diet selection, 721
  - phenylpropanolamine
- Differential effects
  - analgesia, 27, 397
  - anesthesia, 397
  - cold water swim, 27
  - delayed matching-to-sample, 953
  - intrathecal administration, 27
  - methysergide, 27
  - neuroleptics, 953
  - opiates, 397
  - phentolamine, 27
  - pigeons, 953
  - tail flick latency, 397
- Discrimination studies, 279
  - N-methyl-D-aspartate
  - phencyclidine
- DNA development, 365
  - delta-9-tetrahydrocannabinol
  - offspring lethality
  - postnatal brain growth
  - prenatal exposure
  - protein development
  - RNA development
- Domperidone
  - anorexia cachexia, 69
  - apomorphine, 201
  - drug comparisons, 201
  - gastric ulceration, 69
  - haloperidol, 201
  - penile reflexes, 201
  - pimozide, 69
- Dopamine, 255
  - behavioral activation
  - neurokinin- $\alpha$
  - ventral tegmental area
- Dopamine agonists, 1
  - conditioned place preference
  - conditioned taste aversion
  - opposing effects
- Dopamine mechanisms, 593
  - drug interaction
  - exploratory behavior
  - GABA mechanisms
- Dopamine receptors, 417
  - caudate spindle
  - lesions, 6-hydroxydopamine
  - taurine
- Dopaminergic supersensitivity, 941
  - head-twitch response
  - hypermotility
  - neuroleptics
  - stereotyped behavior
- Dopamine transmitters, 317
  - anxiety
  - buspirone
  - stress ulcer
- Dopamine uptake/release, 327
  - cocaine
  - computer simulation
  - in vivo
- Dose-dependent effects, 351
  - amniotic fluid
  - analgesia
  - morphine
  - placenta
  - tail-flick latency
- Doves, 533
  - body weight
  - food intake
  - growth hormone
  - prolactin
  - sex differences
- Drinking, 493
  - angiotensin II
  - intracranial injections
  - tachykinins
- Drug
  - alcohol, 541, 649
  - alprazolam, 541
  - amfonelic acid, 623
  - 6-aminomethyl-3-methyl-4,4-1,2,4-benzothiadiazine-1,1-dioxide, 667
  - amitriptylene, 243
  - amphetamine, 9, 59
  - d-amphetamine, 227, 305, 313, 519, 585, 675, 705, 959
  - (+)-amphetamine, 1
  - apomorphine, 163, 201, 291, 317, 411 593, 605, 717, 807, 871, 941
  - atropine, 381, 515, 547
  - baclofen, 405, 593, 657
  - barbital, 179
  - bicuculline, 405, 751
  - BM123, 337
  - bupropion, 243
  - buspirone, 269, 317, 567
  - butylscopolamine, 405
  - BW 501C67, 475
  - caffeine, 579, 927
  - carbachol, 169, 209
  - carbamazepine, 153
  - $\beta$ -CCE, 767
  - CGS 8216, 375, 767
  - CGS 9896, 249
  - CGS 10746B, 817
  - charybdotoxin, 187
  - chloramphenicol, 933

p-chloroamphetamine, 135  
 chlordiazepoxide, 249, 313, 371, 959  
 l-(m-chlorophenyl) piperazine, 345  
 m-chlorophenylpiperazine, 305, 567  
 chlorpromazine, 941, 953, 959  
 cimetidine, 107  
 clenbuterol, 807  
 clomipramine, 103, 807  
 clonazepam, 153  
 clonidine, 33, 87  
 clozapine, 519  
 cocaine, 327, 387, 623, 877  
 cycloheximide, 405  
 cyproheptadine, 81, 345  
 DALA, 825  
 2-deoxyglucose, 481  
 desipramine, 153, 243, 807  
 diazepam, 15, 153, 541, 597, 693, 709, 733, 959  
 5,6-dihydroxytryptamine, 135  
 diisopropylfluorophosphate, 15  
 1-(2,5-dimethoxyphenyl-4-iodo)-2-aminopropane, 305  
 diphenylhydantoin, 153  
 DL-2-amino-7-phosphonoheptanoic acid, 153  
 DMCM, 249  
 domperidone, 69, 201  
 doxepin, 81  
 ethanol, 129, 163, 179, 215, 375, 597, 617, 667, 733, 751, 757, 761, 767, 877, 893, 909, 945, 949  
 ethosuximide, 153  
 etomidate, 153  
 fenfluramine, 97, 305, 585  
 d-fenfluramine, 773  
 FG 7142, 751, 761, 767  
 flumazenil, 733, 761  
 flunarizine, 153  
 fluoxetine, 475  
 fluphenazine, 941  
 flurazepam, 453  
 gepirone, 269  
 haloperidol, 201, 317, 515, 519, 817, 861, 941  
 hemicholinium-3, 547  
 histidine, 81  
 8-hydroxy-2-(di-n-propylamino) tetralin, 305  
 6-hydroxydopamine, 357, 605  
 5-hydroxytryptamine, 855  
<sup>14</sup>C-5-hydroxytryptamine, 135  
 ICI-154, 129, 43  
 imipramine, 97, 807  
 ketamine, 153  
 ketanserin, 641, 899  
 levorphanol, 43  
 lithium chloride, 909  
 lorazepam, 937  
 loxapine, 953  
 LY53857, 475  
 marijuana, 649  
 MDE, 817  
 MDMA, 239, 817  
 mephenytoin, 233, 787  
 meprobamate, 153  
 3-mercaptopropionic acid, 453  
 metergoline, 475  
 methamphetamine, 9, 411  
 methionine sulfoximine, 797  
 5-methoxy-N,N-dimethyltryptamine, 839  
 5-methoxy-N,N-dimethyltryptamine hydrogen oxalate, 305  
 methsuximide, 787  
 N-methyl-D-aspartate, 279  
 methylphenidate, 675  
 methysergide, 27, 899  
 metoclopramide, 941  
 morphine, 63, 123, 193, 351, 393, 397, 431, 439, 561, 641, 825, 855, 893, 933, 959  
 MR 2034, 825  
 muscimol, 15, 405  
 naloxone, 43, 129, 371, 393, 397, 481, 683, 709, 791  
 naltrexone, 33, 63  
 nicotine, 265, 617, 713  
 nomifensine, 243  
<sup>3</sup>H-noradrenalin, 135  
 norepinephrine, 209  
 norfenfluramine, 305, 817  
 8-OH-DPAT, 567  
 oxotremorine, 169, 175, 345  
 para-chloroamphetamine, 499  
 parachlorophenylalanine, 509, 899  
 PD-117302, 425, 899  
 pentobarbital, 179, 249, 397, 459, 597, 667, 693, 709, 959  
 pentylenetetrazole, 249, 751, 867  
 phencyclidine, 279, 927  
 phencyclidine hydrochloride, 893  
 phenobarbital, 153, 693  
 phenobarbitone, 733  
 phenoxybenzamine, 87, 515  
 phentolamine, 27  
 phenylephrine, 87  
 phenylpropanolamine, 721  
 physostigmine, 405, 627, 633  
 picrotoxin, 405, 709  
 pimozone, 69, 779, 845  
 pirenperone, 305, 641, 817  
 PMA, 9  
 PMMA, 9  
 prazosin, 573, 899  
 promethazine, 81  
 propranolol, 515, 573  
 purine, 579  
 pyridostigmine, 381  
 quinpirole, 1  
 quipazine, 941  
 ritanserin, 475, 899  
 RO 15-1788, 101, 249, 375  
 RO 15-3505, 751, 761  
 RO 15-4513, 375, 733, 751, 757, 761, 767, 945  
 RO 17-1812, 761  
 sabeluzole, 153  
 SCH 23390, 941  
 scopolamine, 175, 405, 547, 633  
 secobarbital, 459  
 serotonin, 773  
 (±)SKF-10,047, 43  
 SKF 38393, 1  
 SL 75 102, 249  
 sodium valproate, 153  
 soman, 633  
 sulpiride, 953  
 sultopride, 941  
 taurine, 411, 417, 667  
 temazepam, 611  
 Δ-9-tetrahydrocannabinol, 365, 893  
 TFMPP, 37, 53  
 THIP, 657  
 thioridazine, 519, 941  
 thiothixine, 953  
 1-(m-trifluoromethylphenyl) piperazine, 305  
 U-50,488, 43, 899  
 urethane, 397  
 xylamidine, 475  
 yohimbine, 89, 321  
 zimelidine, 243  
 ZK 93426, 761  
 Drug addiction model, 605  
   classical conditioning  
   lesions, 6-hydroxydopamine  
   rotational behavior  
 Drug-admixed food, 123  
   morphine  
   morphine dependence  
 Drug comparisons  
   γ-aminobutyric acid, 411  
   apomorphine, 201  
   caudate spindle, 411  
   domperidone, 201  
   haloperidol, 201  
   penile reflexes, 201  
   taurine, 411  
 Drug conditioning, 579  
   caffeine  
   conditioned taste aversion  
 Drug discrimination  
   benzodiazepine receptor, 249  
   CGS 9896, 249  
   MDMA, 239, 817  
   norfenfluramine, 305  
   rapid training method, 239  
   serotonergic-dopaminergic mediation  
   817  
   serotonin mediation, 305  
   stimulus antagonism, 249  
 Drug interactions  
   antinociception, 641  
   anxiety, 761  
   benzodiazepine receptor, 733  
   benzodiazepine receptor ligands, 761  
   cardiovascular effects, 877  
   CGS 8216, 375  
   cocaine, 877  
   diazepam, 597  
   dopamine mechanisms, 593  
   ethanol, 375, 597, 733, 761, 877  
   ethanol tolerance, 617  
   exploratory behavior, 593, 761  
   GABA mechanisms, 593  
   human studies, male, 877  
   hypothermia, 617  
   instrumental behaviors, 597  
   ketanserin, 641  
   locomotor activity, 761  
   morphine, 641  
   nicotine, 617  
   partial inverse agonist, 733  
   pentobarbital, 597  
   pirenperone, 641  
   RO 15-1788, 375, 597  
   RO 15-4513, 375, 597, 733  
   selective breeding, 667  
   schedule-controlled responding, 375  
   sleep time, ethanol induced, 667  
   tail-flick latency, 641  
   taurine, 667  
 Drug/peptide comparisons, 439  
   [D-Arg<sup>2</sup>]-dermorphin  
   morphine  
   route of administration

- Eating, 825
  - cannula-mapping
  - opioid antagonists
- Enantiomers, 475
  - fluoxetine
  - food intake
  - serotonin antagonists
- $\beta$ -Endorphin, 75
  - cholesterol
  - cingulotomy
  - corticosterone
  - plasma
  - stress
  - triglycerides
- Ethanol
  - alcohol-preferring/alcohol-nonpreferring rat comparisons, 215
  - anticonvulsant effects, 751
  - anxiety, 761
  - apomorphine, 163
  - attenuation, 909
  - barbital, 179
  - benzodiazepine/GABA receptor complex, 751
  - benzodiazepine receptor, 733
  - benzodiazepine receptor ligands, 761
  - cardiovascular effects, 877
  - CGS 8216, 375
  - chronic treatment, 179
  - cocaine, 877
  - conditioned emotional response, 949
  - conditioned taste aversion, 909
  - conflict test, 757
  - cross attenuation, 909
  - cross tolerance, 179
  - diazepam, 597
  - drug interactions, 375, 597, 733, 761, 877
  - ethanol aversion, 215
  - ethanol intake, 949
  - exploration, 761
  - food intake, 893
  - GABA receptor complex, 767
  - human studies, male, 877
  - ionizing radiation, 909
  - instrumental behaviors, 597
  - lethality, 945
  - lithium chloride, 909
  - locomotor activity, 761
  - morphine, 893
  - motility, 163
  - naloxone, 129
  - partial inverse agonist, 733
  - pentobarbital, 179, 597
  - phencyclidine hydrochloride, 893
  - reaction time, 757
  - RO 15-1788, 375, 597
  - RO 15-4513, 375, 597, 733, 751, 757, 767, 945
  - schedule-controlled responding, 375
  - strain differences, 129
  - sucrose-fading procedure, 949
  - $\Delta$ -9-tetrahydrocannabinol, 893
  - Tyr-MIF-1, 129
  - volitional drinking, 129
  - withdrawal, 163
- Ethanol aversion, 215
  - alcohol-preferring/alcohol-nonpreferring rat comparisons
  - ethanol
- Ethanol intake, 949
  - Conditioned Emotional Response
    - ethanol
      - sucrose-fading procedure
- Ethanol tolerance, 617
  - drug interaction
  - hypothermia
  - nicotine
- Experimental diabetes, 807
  - $\beta$ -adrenoceptors
  - tricyclics
- Exploration, 761
  - anxiety
  - benzodiazepine receptor ligands
  - drug interactions
  - ethanol
  - locomotor activity
- Exploratory behavior
  - dopamine mechanisms, 593
  - drug interaction, 593
  - GABA mechanisms, 593
  - male/female comparisons, 63
  - morphine, 63
  - naltrexone, 63
  - neonatal treatment, 63
  - sexual behavior, 63
- Exponential data-analysis, 803
  - passive-avoidance behavior
- Fat intake
  - carbohydrate, 773
  - d-fenfluramine, 773
  - hyperphagia, diet-induced, 773
  - peripheral administration, 113
  - serotonin, 113, 773
- Fenfluramine
  - d-amphetamine, 585
  - baboons, 585
  - food intake, 97, 585
  - imipramine, 97
  - locomotor activity, 97
  - long-term treatment, 97
- d-Fenfluramine, 773
  - carbohydrate
  - fat intake
  - hyperphagia, diet-induced
  - serotonin
- Feeding
  - aggression, 43
  - analgesia, 43
  - anorexia, 209
  - carbachol, 209
  - hypothalamus, 209
  - locomotor activity, 43
  - mice, male, 43
  - norepinephrine, 209
  - opiate agonists, 43
  - opiate antagonists, 43
  - rats, tumor bearing, 209
- Feeding behavior
  - antihistamines, 81
  - PD-117302, 425
  - strain differences, 425
- Filter pad validation, 905
  - human studies, males
  - plasma nicotine
  - quantified smoke delivery
- Fluid consumption, 313
  - anxiety
  - chlordiazepoxide
  - neophobia
- Fluorophotometric assay, 287
  - high performance liquid chromatography with electrochemical detection
  - urinary catecholamines
- Fluoxetine, 475
  - enantiomers
  - food intake
  - serotonin antagonists
- Flurazepam, 453
  - anesthetic effects
  - anticonvulsant effects
  - hypothermic effects
  - selective breeding
- Food deprivation, 487
  - food maze performance
  - plasma hormone levels
  - water maze performance
- Food intake
  - d-amphetamine, 585
  - baboons, 585
  - body weight, 533
  - buspirone, 567
  - cats, 297
  - m-chlorophenylpiperazine, 567
  - cholecystokinin, 297
  - doves, 533
  - enantiomers, 475
  - ethanol, 893
  - fenfluramine, 97, 585
  - fluoxetine, 475
  - growth hormone, 533
  - human satietin, 21
  - imipramine, 97
  - locomotor activity, 97, 567
  - long-term treatment, 97
  - morphine, 893
  - 8-OH-DPAT, 567
  - phencyclidine hydrochloride, 893
  - prolactin, 533
  - route of administration, 21
  - serotonin antagonists, 475
  - sex differences, 533
  - strain differences, 567
  - structure-activity relationship, 297
  - $\Delta$ -9-tetrahydrocannabinol, 893
  - water intake, 21
- Food maze performance, 487
  - food deprivation
  - plasma hormone levels
  - water maze performance
- Food reward, 861
  - haloperidol
  - neuroleptics
  - positive reinforcement
- Food selection, 149
  - human studies, males
  - tryptophan
- Formalin test, 855
  - analgesia
  - 5-hydroxytryptamine
  - morphine
- Freund's complete adjuvant, 445
  - hindpaw
  - inflammation
  - locomotor behavior
  - nociceptive thresholds
- GABAergic blockade, 193
  - aversion
  - medial hypothalamus

morphine  
 periaqueductal gray  
 GABAergic neuronal system, 405  
 amnesia  
 cholinergic neuronal system  
 cycloheximide  
 GABA mechanisms, 593  
 dopamine mechanisms  
 drug interaction  
 exploratory behavior  
 GABA receptor complex, 767  
 ethanol  
 RO 15-4513  
 Galanthamine, 141  
 lesions, nucleus basalis  
 magnocellularis  
 spatial memory  
 Gastric ulceration, 69  
 anorexia cachexia  
 domperidone  
 pimoziide  
 Genital grooming, 717  
 apomorphine  
 luteinizing hormone releasing hormone  
 yawning  
 Gepirone, 269  
 buspirone  
 rats, wild  
 taming  
 Gonadal hormones, naltrexone effects, 683  
 monkeys  
 pituitary hormones, naltrexone effects  
 sex differences  
 Gonadotropin-releasing hormone, 725  
 rats, pregnant  
 sexual behavior, postpartum  
 Growth hormone, 533  
 body weight  
 doves  
 food intake  
 prolactin  
 sex differences  
  
 Haloperidol  
 apomorphine, 201  
 domperidone, 201  
 drug comparisons, 201  
 food reward, 861  
 neuroleptics, 861  
 penile reflexes, 201  
 positive reinforcement, 861  
 Hamsters, 885  
 aging  
 hippocampus  
 hypoactivity  
 obesity  
 serotonin  
 Handling habituation, 541  
 acute treatment  
 anxiety  
 avoidance acquisition  
 benzodiazepines  
 chronic treatment  
 Head-twitch response, 941  
 dopaminergic supersensitivity  
 hypermotility  
 neuroleptics  
 stereotyped behavior  
 Heart rate, 561  
 morphine  
  
 sensitivity  
 tolerance  
 Hedonic effects, 779  
 motor effects  
 operant behavior  
 pimoziide  
 High performance liquid chromatography  
 with electrochemical detection, 287  
 fluorophotometric assay  
 urinary catecholamines  
 Hindpaw, 445  
 Freund's complete adjuvant  
 inflammation  
 locomotor behavior  
 nociceptive thresholds  
 Hippocampus, 885  
 aging  
 hamsters  
 hypoactivity  
 obesity  
 serotonin  
 Hormone  
 corticosterone, 75  
 estrogen, 573  
 gonadotropin-releasing hormone, 725  
 growth hormone, 533  
 pregnanes, 919  
 progesterone, 919  
 prolactin, 533  
 Housing, 59  
 amphetamine  
 intravenous self-administration  
 5-HT antagonists, 899  
 kappa agonists  
 locomotor activity  
 5-HT<sub>1B</sub> receptors, 53  
 TFMPP  
 Human satietin, 21  
 food intake  
 route of administration  
 water intake  
 Human studies  
 alcohol, 649  
 behavioral effects, 649  
 blood pressure, 387  
 cardiovascular activity, 387  
 cocaine, 387  
 comparison profiles, 649  
 marijuana, 649  
 subjective effects, 649  
 task performance, 387  
 Human studies, males  
 cardiovascular effects, 877  
 cocaine, 877  
 drug interactions, 877  
 ethanol, 877  
 filter pad validation, 905  
 food selection, 149  
 plasma nicotine, 905  
 quantified smoke delivery, 905  
 tryptophan, 149  
 Human studies, smokers, 93  
 carbon monoxide  
 cigarettes  
 6-Hydroxydopamine, 357  
 maze learning  
 motor activity  
 neonatal administration  
 5-Hydroxytryptamine, 855  
 analgesia  
 formalin test  
 morphine  
  
 Hypermotility, 941  
 dopaminergic supersensitivity  
 head-twitch response  
 neuroleptics  
 stereotyped behavior  
 Hyperphagia, diazepam-induced, 709  
 hyperphagia, pentobarbital-induced  
 naloxone  
 picrotoxin  
 rats, nondeprived  
 Hyperphagia, diet-induced, 773  
 carbohydrate  
 fat intake  
 d-fenfluramine  
 serotonin  
 Hyperphagia, pentobarbital-induced, 709  
 hyperphagia, diazepam-induced  
 naloxone  
 picrotoxin  
 rats, nondeprived  
 Hypoactivity, 885  
 aging  
 hamsters  
 hippocampus  
 obesity  
 serotonin  
 Hypomotility, 291  
 apomorphine  
 conditioned avoidance  
 luteinizing hormone releasing hormone  
 spontaneous motor activity  
 Hypothalamus, 209  
 anorexia  
 carbachol  
 feeding  
 norepinephrine  
 rats, tumor-bearing  
 Hypothermia  
 drug interaction, 617  
 ethanol tolerance, 617  
 methionine sulfoximine, 797  
 nicotine, 617  
 Hypothermic effects, 453  
 anesthetic effects  
 anticonvulsant effects  
 flurazepam  
 selective breeding  
  
 Imipramine, 97  
 fenfluramine  
 food intake  
 locomotor activity  
 long-term treatment  
 Inflammation, 445  
 Freund's complete adjuvant  
 hindpaw  
 locomotor behavior  
 nociceptive thresholds  
 Insomnia, 509  
 parachlorophenylalanine  
 ponto-geniculo-occipital waves  
 Instrumental behaviors, 597  
 diazepam  
 drug interactions  
 ethanol  
 pentobarbital  
 Ro 15-1788  
 Ro 15-4513  
 Interactive effects, 927  
 behavioral dependence

- caffeine
- monkeys
- phencyclidine
- Intermittent administration, 871
  - apomorphine
  - locomotor activity
  - stereotypy
- Intracranial injections, 493
  - angiotensin II
  - drinking
  - tachykinins
- Intracranial self-administration, 243
  - antidepressant drugs
  - long-term administration
- Intrastriatal injection, 153
  - anticonvulsants
  - barrel rotation
  - intrastratial injection
- Intrathecal administration, 27
  - analgesia
  - cold water swim
  - differential effects
  - methysergide
  - phentolamine
- Intravenous self-administration
  - amfonelic acid, 623
  - amphetamine, 59
  - cocaine, 623
  - housing, 59
- In vivo, 327
  - cocaine
  - computer simulation
  - dopamine uptake/release
- Ionizing radiation, 909
  - attenuation
  - conditioned taste aversion
  - cross-attenuation
  - ethanol
  - lithium chloride
- Kappa agonists, 899
  - 5-HT antagonists
  - locomotor activity
- Ketanserin, 641
  - antinociception
  - drug interactions
  - morphine
  - pirenperone
  - tail-flick latency
- Kindling, 867
  - pentyleneetetrazol
- Lateral hypothalamus, 547
  - brainstem
  - cholinergic antagonists
  - self-stimulation
  - ventral tegmentum
- Lateral ventricle
  - carbachol, 169
  - oxotremorine, 169, 175
  - preoptic area, 169, 175
  - rats, experienced males, 169
  - rats, males, 175
  - scopolamine, 175
  - sexual behavior, 169, 175
- Lesions, 6-hydroxydopamine
  - caudate spindle, 417
  - classical conditioning, 605
  - dopamine receptors, 417
  - drug addiction model, 605
  - rotational behavior, 605
  - taurine, 417
- Lesions, nucleus basalis magnocellularis, 141
  - galanthamine
  - spatial memory
- Lethality, 945
  - ethanol
  - RO 15-4513
- Lithium chloride, 909
  - attenuation
  - conditioned taste aversion
  - cross-attenuation
  - ethanol
  - ionizing radiation
- Locomotor activity
  - aggression, 43
  - d-amphetamine, 675
  - analgesia, 43
  - anxiety, 761
  - apomorphine, 871
  - BALB/cByJ mice, 675
  - benzodiazepine receptor ligands, 761
  - buspirone, 567
  - chlordiazepoxide, 371
  - m-chlorophenylpiperazine, 567
  - chronic administration, 675
  - drug interactions, 761
  - ethanol, 761
  - exploration, 761
  - feeding, 43
  - fenfluramine, 97
  - food intake, 97, 567
  - 5-HT antagonists, 899
  - imipramine, 97
  - intermittent administration, 871
  - kappa agonists, 899
  - long-term treatment, 97
  - methylphenidate, 675
  - mice, male, 43
  - naloxone, 371
  - 8-OH-DPAT, 567
  - opiate agonists, 43
  - opiate antagonists, 43
  - opioid mechanisms, 371
  - stereotypy, 871
  - strain differences, 567
- Locomotor behavior, 445
  - Freund's complete adjuvant
  - hindpaw
  - inflammation
  - nociceptive thresholds
- Long-term administration, 243
  - antidepressant drugs
  - intracranial self-administration
- Long-term treatment, 97
  - fenfluramine
  - food intake
  - imipramine
  - locomotor activity
- Lorazepam, 937
  - sensitization
  - tolerance
  - withdrawal
- Lordosis, 573
  - adrenergic receptor antagonists
  - lutinizing hormone-releasing hormone
  - sexual experience
- Lordosis stimulation, 919
  - pregnanes
- progesterone metabolism
- progesterone receptors
- Lumbosacral injection, 657
  - $\gamma$ -aminobutyric acid antagonists
  - penile reflexes
  - rats, male
  - sexual behavior
- Luteinizing hormone releasing hormone
  - adrenergic receptor antagonists, 573
  - apomorphine, 291, 717
  - conditioned avoidance, 291
  - genital grooming, 717
  - hypomotility, 291
  - lordosis, 573
  - sexual experience, 573
  - spontaneous motor activity, 291
  - yawning, 717
- Male/female comparisons, 63
  - exploratory behavior
  - morphine
  - naltrexone
  - neonatal treatment
- Marijuana, 649
  - behavioral effects
  - comparison profiles
  - human studies
  - subjective effects
- Maze learning, 357
  - 6-hydroxydopamine
  - motor activity
  - neonatal administration
- MDMA
  - drug discrimination, 239, 817
  - rapid training method, 239
  - serotonergic-dopaminergic mediation
  - 817
- Medial hypothalamus, 193
  - aversion
  - GABAergic blockade
  - morphine
  - periaqueductal gray
- Mephentoin
  - methsuximide, 787
  - pigeons, 233, 787
  - reaction time, 787
  - schedule-controlled responding, 233
- Methamphetamine, 9
  - behavioral investigation
  - PMMA
- Methionine sulfoximine, 797
  - hypothermia
- Method, 287
  - fluorophotometric assay
  - high performance liquid chromatography with electrochemical detection
- Methsuximide, 787
  - mephentoin
  - pigeons
  - reaction time
- N-Methyl-D-aspartate, 279
  - discrimination studies
  - phencyclidine
- Methylphenidate, 675
  - d-amphetamine
  - BALB/cByJ mice
  - chronic administration
  - locomotor activity
- Methysergide, 27



- analgesia
  - cold water swim
  - differential effects
  - intrathecal administration
  - phentolamine
- Mice, male, 43
  - aggression
  - analgesia
  - feeding
  - locomotor activity
  - opiate agonists
  - opiate antagonists
- Midbrain periaqueductal grey, 791
  - aggression
  - cats
  - naloxone
- Monetary reinforcement, 227
  - d*-amphetamine
  - concurrent schedule
  - social interaction
  - time allocation
- Monkeys
  - atropine, 381
  - behavioral dependence, 927
  - caffeine, 927
  - cardiac response, 381
  - gonadal hormones, naltrexone effects, 683
  - interactive effects, 927
  - opiate/adrenergic receptor blockade, 223
  - parasympathetic activity, 381
  - phencyclidine, 927
  - pituitary hormones, naltrexone effects, 683
  - pyridostigmine, 381
  - sex differences, 683
  - vocalization, 223
- Morphine
  - amniotic fluid, 351
  - analgesia, 351, 855
  - antinociception, 641
  - aversion, 193
  - chloramphenicol, 933
  - [D-Arg<sup>2</sup>]-dermorphin, 439
  - dose-dependent effects, 351
  - drug-admixed food, 123
  - drug interactions, 641
  - drug/peptide comparisons, 439
  - ethanol, 893
  - exploratory behavior, 63
  - food intake, 893
  - formalin test, 855
  - GABAergic blockade, 193
  - heart rate, 561
  - 5-hydroxytryptamine, 855
  - ketanserin, 641
  - male/female comparisons, 63
  - medial hypothalamus, 193
  - morphine dependence, 123
  - naloxone, 393
  - naltrexone, 63
  - neonatal rat, 431
  - neonatal treatment, 63
  - opiate tolerance, 431
  - opiate withdrawal, 431
  - penile reflexes, 393
  - periaqueductal gray, 139
  - phencyclidine hydrochloride, 893
  - pirenerone, 641
  - placenta, 351
  - route of administration, 439
  - self-stimulation, 933
  - seminal emission, 393
  - sensitivity, 561
  - sexual behavior, 63
  - tail-flick latency, 351, 641
  - $\Delta$ -9-tetrahydrocannabinol, 893
  - tolerance, 561
- Morphine dependence, 123
  - drug-admixed food
  - morphine
- Motility, 163
  - apomorphine
  - ethanol
  - withdrawal
- Motor activity, 357
  - 6-hydroxydopamine
  - maze learning
  - neonatal administration
- Motor effects, 779
  - hedonic effects
  - operant behavior
  - pimozide
- Motor recovery, 187
  - charybdotoxin
  - spinal cord injury
- Naloxone
  - aggression, 791
  - cats, 791
  - cerebral metabolism, 481
  - chlordiazepoxide, 371
  - 2-deoxyglucose, 481
  - ethanol, 129
  - hyperphagia, diazepam-induced, 709
  - hyperphagia, pentobarbital-induced, 709
  - locomotor activity, 371
  - midbrain periaqueductal grey, 791
  - morphine, 393
  - opioid antagonists, 481
  - opioid mechanisms, 371
  - penile reflexes, 393
  - picrotoxin, 709
  - rats, nondeprived, 709
  - seminal emission, 393
  - strain differences, 129
  - Tyr-MIF-1, 129
  - volitional drinking, 129
- Naltrexone
  - $\alpha_2$ -adrenoceptors, 33
  - chronic stress, 33
  - clonidine, 33
  - exploratory behavior, 63
  - male/female comparisons, 63
  - morphine, 63
  - neonatal treatment, 63
  - sexual behavior, 63
- Neonatal administration
  - aggression, shock-induced, 103
  - animal depression model, 103
  - clomipramine, 103
  - 6-hydroxydopamine, 357
  - maze learning, 357
  - motor activity, 357
- Neonatal rat, 431
  - morphine
  - opiate tolerance
  - opiate withdrawal
- Neonatal treatment, 63
  - exploratory behavior
  - male/female comparisons
  - morphine
  - naltrexone
  - sexual behavior
- Neophobia, 313
  - anxiety
  - chlordiazepoxide
  - fluid consumption
- Neurokinin- $\alpha$ 
  - behavioral activation
  - dopamine
  - ventral tegmental area
- Neuroleptics
  - delayed matching-to-sample, 953
  - differential effects, 953
  - dopaminergic supersensitivity, 941
  - food reward, 861
  - head-twitch response, 941
  - haloperidol, 861
  - hypermotility, 941
  - pigeons, 953
  - positive reinforcement, 861
  - stereotyped behavior, 941
- Neurotransmitter turnover rates, 523
  - punishment
- Nicotine
  - acute exposure, 265
  - analgesia, 265
  - chronic exposure, 265
  - drug interaction, 617
  - ethanol tolerance, 617
  - hypothermia, 617
  - restraint stress, 265
  - sustained release, 713
  - tolerance development, 265
- Nociceptive thresholds, 445
  - Freund's complete adjuvant
  - hindpaw
  - inflammation
  - locomotor behavior
- Nonopioid analgesia, 107
  - cimetidine
  - cold-water swims
  - opioid analgesia
- Norepinephrine, 209
  - anorexia
  - carbachol
  - feeding
  - hypothalamus
  - rats, tumor bearing
- Norfenfluramine, 305
  - drug discrimination
  - serotonin mediation
- Obesity, 885
  - aging
  - hamsters
  - hippocampus
  - hypoactivity
  - serotonin
- Offspring effects, 839
  - brain development
  - prenatal stress
  - serotonergic system
- Offspring lethality, 365
  - delta-9-tetrahydrocannabinol
  - DNA development
  - postnatal brain growth
  - prenatal exposure
  - protein development

- RNA development
- 8-OH-DPAT, 567
  - bupirone
  - M-chlorophenylpiperazine
  - food intake
  - locomotor activity
  - strain differences
- Operant behavior, 779
  - hedonic effects
  - motor effects
  - pimozide
- Opiate/adrenergic receptor blockade, 223
  - monkeys
  - vocalization
- Opiate agonists, 43
  - aggression
  - analgesia
  - feeding
  - locomotor activity
  - mice, male
  - opiate antagonists
- Opiate antagonists, 43
  - aggression
  - analgesia
  - feeding
  - locomotor activity
  - mice, male
  - opiate agonists
- Opiates, 397
  - analgesia
  - anesthesia
  - differential effects
  - tail flick latency
- Opiate tolerance, 431
  - morphine
  - neonatal rat
  - opiate withdrawal
- Opiate withdrawal, 431
  - morphine
  - neonatal rat
  - opiate tolerance
- Opioid agonists, 825
  - cannula-mapping
  - eating
- Opioid analgesia, 107
  - cimetidine
  - cold-water swims
  - nonopioid analgesia
- Opioid antagonists, 481
  - cerebral metabolism
  - 2-deoxyglucose
  - naloxone
- Opioid mechanisms, 371
  - chlordiazepoxide, 371
  - locomotor activity
  - naloxone
- Opposing effects, 1
  - conditioned place preference
  - conditioned taste aversion
  - dopamine agonists
- Oral administration, 467
  - aluminum
  - chronic administration
  - passive avoidance
- Oxotremorine
  - carbachol, 169
  - lateral ventricle, 169, 175
  - preoptic area, 169, 175
  - rats, experienced males
  - rats, males, 175
  - scopolamine, 175
  - sexual behavior, 169, 175
- Parachlorophenylalanine, 509
  - insomnia
  - ponto-geniculo-occipital waves
- Parasympathetic activity, 381
  - atropine
  - cardiac response
  - monkeys
  - pyridostigmine
- Partial inverse agonist, 733
  - benzodiazepine receptor
  - drug interactions
  - ethanol
  - RO 15-4513
- Passive avoidance
  - aging, 611
  - aluminum, 467
  - chronic administration, 467
  - exponential data-analysis, 803
  - oral administration, 467
  - serotonergic system, 499
  - sex differences, 499
  - temazepam, 611
- PD-117302, 425
  - feeding behavior
  - strain differences
- Penile reflexes
  - $\gamma$ -aminobutyric acid antagonists, 657
  - apomorphine, 201
  - domperidone, 201
  - drug comparisons, 201
  - haloperidol, 201
  - lumbar injection, 657
  - morphine, 393
  - naloxone, 393
  - rats, male, 657
  - seminal emission, 393
  - sexual behavior, 657
- Pentobarbital
  - aminoxyacetic acid, 693
  - anticonflict effects, 693
  - barbital, 179
  - chronic administration, 459
  - chronic treatment, 179
  - cross-tolerance, 179
  - diazepam, 597, 693
  - drug interactions, 597
  - ethanol, 179, 597
  - instrumental behaviors, 597
  - phenobarbital, 693
  - pigeon/rat comparisons, 459
  - Ro 15-1788, 597
  - Ro 15-4513, 597
  - secobarbital, 459
  - tolerance, 459
- Pentylentetrazol, 867
  - kindling
- Peptide
  - adrenocorticotrophic hormone, 515
  - angiotensin II, 493, 813
  - cholecystokinin, 297
  - [D-Arg<sup>2</sup>]-dermorphin, 439
  - eledoisin, 493
  - $\beta$ -endorphin, 75
  - kassinin, 493
  - luteinizing hormone releasing hormone, 291, 573, 717
  - neurokinin- $\alpha$ , 255
  - Sar-1 Thr-8 angiotensin II, 813
  - satietin, 21
  - substance P, 255, 493
  - Tyr-MIF-1, 129
- Performance, 845
  - current intensity
  - pimozide
  - reward
  - self-stimulation
- Periaqueductal gray, 193
  - aversion
  - GABAergic blockade
  - medial hypothalamus
  - morphine
- Peripheral administration, 113
  - fat intake
  - serotonin
- Phencyclidine, 927
  - behavioral dependence
  - caffeine
  - discrimination studies, 279
  - interactive effects, 927
  - N-methyl-D-aspartate, 279
  - monkeys, 927
- Phencyclidine hydrochloride, 893
  - delta-9-tetrahydrocannabinol
  - ethanol
  - food intake
  - morphine
- Phenobarbital, 693
  - aminoxyacetic acid
  - anticonflict effects
  - diazepam
  - pentobarbital
- Phentolamine, 27
  - analgesia
  - cold water swim
  - differential effects
  - intrathecal administration
  - methysergide
- Phenylpropanolamine, 721
  - diet selection
- Physostigmine, 633
  - continuous administration, 627, 633
  - scopolamine
  - soman
  - soman activity
  - toxicity study, 627
- Picrotoxin, 709
  - hyperphagia, diazepam-induced
  - hyperphagia, pentobarbital-induced
  - naloxone
  - rats, nondeprived
- Pigeon/rat comparisons, 459
  - chronic administration
  - pentobarbital
  - secobarbital
  - tolerance
- Pigeons
  - delayed matching-to-sample, 953
  - differential effects, 953
  - mephenytoin, 233, 787
  - methsuximide, 787
  - neuroleptics, 953
  - reaction time, 787
  - schedule-controlled responding, 233
- Pimozide
  - anorexia cachexia, 69
  - current intensity, 845
  - domperidone, 69
  - gastric ulceration, 69
  - hedonic effects, 779
  - motor effects, 779
  - operant behavior, 779
  - performance, 845
  - reward, 845
  - self-stimulation, 845

- D-Pipecolic acid, 833
  - prolyl-leucyl- glycineamide
  - retrograde amnesia
- Pirenperone, 641
  - antinociception
  - drug interactions
  - ketanserin
  - morphine
  - tail-flick latency
- Pituitary hormones, naltrexone effects, 683
  - gonadal hormones, naltrexone effects
  - monkeys
  - sex differences
- Placenta, 351
  - amniotic fluid
  - analgesia
  - dose-dependent effects
  - morphine
  - tail-flick latency
- Plasma, 75
  - cholesterol
  - cingulotomy
  - corticosterone
  - $\beta$ -endorphin
  - stress
  - triglycerides
- Plasma hormone levels, 487
  - food deprivation
  - food maze performance
  - water maze performance
- Plasma nicotine, 905
  - filter pad validation
  - human studies, male
  - quantified smoke delivery
- PMMA, 9
  - behavioral investigation
  - methamphetamine
- Ponto-geniculo-occipital waves, 509
  - insomnia
  - parachlorophenylalanine
- Positive reinforcement, 861
  - food reward
  - haloperidol
  - neuroleptics
- Postnatal brain growth, 365
  - delta-9-tetrahydrocannabinol
  - DNA development
  - offspring lethality
  - prenatal exposure
  - protein development
  - RNA development
- [<sup>3</sup>H]-Prazosin binding, 505
  - aging
  - cortex
- Pregnanes, 919
  - lordosis stimulation
  - progesterone metabolism
  - progesterone receptors
- Prenatal exposure, 365
  - delta-9-tetrahydrocannabinol
  - DNA development
  - offspring
  - postnatal brain growth
  - protein development
  - RNA development
- Prenatal stress, 839
  - brain development
  - offspring effects
  - serotonergic system
- Preoptic area
  - carbachol, 169
  - lateral ventricle, 169, 175
  - oxotremorine, 169, 175
  - rats, experienced males, 169
  - rats, males, 175
  - scopolamine, 175
  - sexual behavior, 169, 175
- Progesterone metabolism, 919
  - lordosis stimulation
  - pregnanes
  - progesterone receptors
- Progesterone receptors, 919
  - lordosis stimulation
  - pregnanes
  - progesterone metabolism
- Prolactin, 533
  - body weight
  - doves
  - food intake
  - growth hormone
  - sex differences
- Prolyl-leucyl-glycinamide, 833
  - D-pipecolic acid
  - retrograde amnesia
- Protein development, 365
  - delta-9-tetrahydrocannabinol
  - DNA development
  - offspring
  - postnatal brain growth
  - prenatal exposure
  - RNA development
- Psychopharmacological profile, 37
  - TFMPP
- Punishment, 523
  - neurotransmitter turnover rates
- Pyridostigmine, 381
  - atropine
  - cardiac response
  - monkeys
  - parasympathetic response
- Quantified smoke delivery, 905
  - filter pad validation
  - human studies, male
  - plasma nicotine
- Quinolinic acid, 153
  - anticonvulsants
  - barrel rotation
  - intrastratial injection
- Rapid training method, 239
  - drug discrimination
  - MDMA
- Rats, experienced males, 169
  - carbachol
  - lateral ventricle
  - oxotremorine
  - preoptic area
  - sexual behavior
- Rats, male
  - $\gamma$ -aminobutyric acid antagonists, 657
  - lateral ventricle, 175
  - lumbar injection, 657
  - oxotremorine, 175
  - penile reflexes, 657
  - preoptic area, 175
  - scopolamine, 175
  - sexual behavior, 175, 657
- Rats, nondeprived, 709
  - hyperphagia, diazepam-induced
  - hyperphagia, pentobarbital-induced
  - naloxone
  - picrotoxin
  - rats, nondeprived
- Rats, pregnant, 725
  - gonadotropin-releasing hormone
  - sexual behavior, postpartum
- Rats, tumor bearing, 209
  - anorexia
  - carbachol
  - feeding
  - hypothalamus
  - norepinephrine
- Rats, wild, 269
  - buspirone
  - gepirone
  - taming
- Reaction time
  - conflict test, 757
  - ethanol, 757
  - mephenytoin, 787
  - methsuximide, 787
  - pigeons, 787
  - RO 15-4513, 757
- Receptor blockers, 515
  - active avoidance reflex extinction
  - adrenocorticotropic hormone
- Restraint stress, 265
  - acute exposure
  - analgesia
  - chronic exposure
  - nicotine
  - tolerance development
- Retrograde amnesia, 833
  - D-pipecolic acid
  - prolyl-leucyl-glycinamide
- Reward, 845
  - current intensity
  - performance
  - pimozide
  - self-stimulation
- RNA development, 365
  - delta-9-tetrahydrocannabinol
  - DNA development
  - offspring
  - postnatal exposure
  - prenatal brain growth
  - protein development
- Ro 15-1788
  - CGS 8216, 375
  - diazepam, 597
  - drug interactions, 375, 597
  - ethanol, 597
  - instrumental behaviors, 597
  - pentobarbital, 597
  - Ro 15-4513, 375, 597
  - schedule-controlled responding, 375
- Ro 15-4513
  - anticonvulsant effects, 751
  - benzodiazepine/GABA receptor complex, 751
  - benzodiazepine receptors, 733
  - CGS 8216, 375
  - conflict test, 757
  - diazepam, 597
  - drug interactions, 375, 597, 733
  - ethanol, 375, 597, 733, 751, 757, 767, 945
  - GABA receptor complex, 767
  - instrumental behaviors, 597
  - lethality, 945

- partial inverse agonist, 733
- pentobarbital, 597
- reaction time, 575
- Ro 15-1788, 375, 597
- schedule-controlled responding, 375
- Rotational behavior, 605
  - classical conditioning
  - drug addiction model
  - lesions, 6-hydroxydopamine
- Route of administration
  - [D-Arg<sup>2</sup>]-dermorphin, 439
  - colchicine, 579
  - drug/peptide comparisons, 439
  - food intake, 21
  - human satietin, 21
  - micturition, 579
  - morphine, 439
  - water intake, 21
- Sar-1 Thr-8 angiotensin II, 813
  - angiotensin II
  - alcohol intake
- Scopolamine
  - continuous administration, 633
  - lateral ventricle, 175
  - oxotremorine, 175
  - physostigmine, 633
  - preoptic area, 175
  - rats, males, 175
  - sexual behavior, 175
  - soman, 633
  - soman activity, 633
- Schedule-controlled responding
  - CGS 8216, 375
  - drug interactions, 375
  - ethanol, 375
  - mephentoin, 233
  - pigeon, 233
  - Ro 15-1788, 375
  - Ro 15-4513, 375
- Secobarbital, 459
  - chronic administration
  - pentobarbital
  - pigeon/rat comparisons
  - tolerance
- Selective breeding
  - anesthetic effects, 453
  - anticonvulsant effects, 453
  - cholinergic function, 345
  - drug interaction, 667
  - flurazepam, 453
  - hypothermic effects, 453
  - serotonergic sensitivity, 345
  - sleep time, ethanol-induced, 667
  - taurine, 667
- Self-stimulation
  - brainstem, 547
  - chloramphenicol, 933
  - cholinergic antagonists, 547
  - current intensity, 845
  - lateral hypothalamus, 547
  - morphine, 933
  - performance, 845
  - pimozide, 845
  - reward, 845
  - ventral tegmentum, 547
- Seminal emission, 393
  - morphine
  - naloxone
  - penile reflexes
- Sensitivity, 561
  - heart rate
  - morphine
  - tolerance
- Sensitization
  - amphetamine, 705
  - circling behavior, 705
  - lorazepam, 937
  - tolerance, 937
  - withdrawal, 937
- Serotonergic-dopaminergic mediation, 817
  - drug discrimination
  - MDMA
- Serotonergic pathways, 135
  - antinociception
  - p-chloroamphetamine
- Serotonergic sensitivity, 345
  - cholinergic function
  - selective breeding
- Serotonergic system
  - brain development, 839
  - offspring effects, 839
  - passive avoidance, 499
  - prenatal stress, 839
  - sex differences, 499
- Serotonin
  - aging, 885
  - carbohydrate, 773
  - fat intake, 113
  - d-fenfluramine, 773
  - hamster, 885
  - hippocampus, 885
  - hyperphagia, diet-induced, 773
  - hypoactivity, 885
  - obesity, 885
  - peripheral administration, 113
- Serotonin antagonists, 475
  - enantiomers
  - fluoxetine
  - food intake
- Serotonin mediation, 305
  - drug discrimination
  - norfenfluramine
- Sex differences
  - body weight, 533
  - doves, 533
  - food intake, 533
  - gonadal hormones, naltrexone effects, 683
  - growth hormone, 533
  - monkeys, 683
  - passive avoidance, 499
  - pituitary hormones, naltrexone effects, 683
  - prolactin, 533
  - serotonergic system, 499
- Sexual behavior
  - $\gamma$ -aminobutyric acid antagonists, 657
  - carbachol, 169
  - exploratory behavior, 63
  - lateral ventricle, 169, 175
  - lumbar injection, 657
  - male/female comparisons, 63
  - morphine, 63
  - naltrexone, 63
  - neonatal treatment, 63
  - oxotremorine, 169, 175
  - preoptic area, 169, 175
  - penile reflexes, 657
  - rats, experienced males, 169
  - rats, male, 175, 657
  - scopolamine, 175
- Sexual behavior, postpartum, 725
  - gonadotropin-releasing hormone
  - rats, pregnant
- Sexual experience, 573
  - adrenergic receptor antagonists
  - lordosis
  - luteinizing hormone-releasing hormone
- Sleep time, ethanol-induced, 667
  - drug interaction
  - selective breeding
  - taurine
- Social interaction, 227
  - d-amphetamine
  - concurrent schedule
  - monetary reinforcement
  - time allocation
- Soman, 633
  - continuous administration
  - physostigmine
  - scopolamine
  - soman activity
- Soman activity, 633
  - continuous administration
  - physostigmine
  - scopolamine
  - soman
- Spatial memory, 141
  - galanthamine
  - lesions, nucleus basalis magnocellularis
- Spinal cord injury, 187
  - charybdotoxin
  - motor recovery
- Spontaneous alternation, 337
  - avoidance
  - BM123
- Spontaneous motor activity, 291
  - apomorphine
  - conditioned avoidance
  - hypomotility
  - luteinizing hormone releasing hormone
- Stereotyped behavior, 941
  - dopaminergic supersensitivity
  - head-twitch response
  - hypermotility
  - neuroleptics
- Stereotypy
  - d-amphetamine, 519
  - apomorphine, 871
  - atypical antipsychotics, 519
  - intermittent administration, 871
  - locomotor activity, 871
- Stimulus antagonism, 249
  - benzodiazepine receptor
  - CGS 9896
  - drug discrimination
- Strain differences
  - buspirone, 567
  - m-chlorophenylpiperazine
  - ethanol, 129
  - feeding behavior, 425
  - food intake, 567
  - locomotor activity, 567
  - naloxone, 129
  - 8-OH-DPAT, 567
  - PD-117302, 425
  - Tyr-MIF-1, 129
  - volitional drinking, 129
- Stress, 75
  - cholesterol
  - cingulotomy
  - corticosterone

- $\beta$ -endorphin
  - plasma
  - triglycerides
- Stress ulcer, 317
  - anxiety
  - buspirone
  - dopamine transmitters
- Structure-activity relationship, 297
  - cats
  - cholecystokinin
  - food intake
- Subjective effects, 649
  - alcohol
  - behavioral effects
  - comparison profiles
  - human studies
  - marijuana
- Sucrose-fading procedure, 949
  - Conditioned Emotional Response
  - ethanol
  - ethanol intake
- Sustained release, 713
  - nicotine
  
- Tachykinins, 493
  - angiotensin II
  - drinking
  - intracranial injections
- Tail-flick latency
  - amniotic fluid, 351
  - analgesia, 351, 397
  - anesthesia, 397
  - antinociception, 641
  - differential effects, 397
  - dose-dependent effects, 351
  - drug interactions, 641
  - ketanserin, 641
  - morphine, 351, 641
  - opiates, 397
  - pirenerone, 641
  - placenta, 351
- Taming, 269
  - buspirone
  - gepirone
  - rats, wild
- Task performance, 387
  - blood pressure
  - cardiovascular activity
  - cocaine
  - human studies
- Taurine
  - $\gamma$ -aminobutyric acid, 411
  - caudate spindle, 411, 417
  - dopamine receptors, 417
  - drug comparisons, 411
  - drug interaction, 667
  - lesions, 6-hydroxydopamine, 417
  - selective breeding, 667
  - sleep time, ethanol-induced, 667
  
- Temazepam, 611
  - aging
  - passive-avoidance response
- $\Delta$ -9-Tetrahydrocannabinol
  - DNA development, 365
  - ethanol, 893
  - food intake, 893
  - morphine, 893
  - offspring lethality, 365
  - phencyclidine hydrochloride, 893
  - postnatal brain growth, 365
  - prenatal exposure, 365
  - protein development, 365
  - RNA development, 365
- TFMPP
  - psychopharmacological profile, 37
  - 5-HT<sub>1B</sub> receptors, 53
- Thermoregulatory responses, 699
  - acute administration
  - ammonium chloride
  - creatinine
  - urea
- Thigmotaxis, 959
  - anxiolytic activity
- Time allocation, 227
  - d-amphetamine
  - concurrent schedule
  - monetary reinforcement
  - social interaction
- Tolerance
  - heart rate, 561
  - lorazepam, 937
  - morphine, 561
  - sensitivity, 561
  - sensitization, 937
  - withdrawal, 937
- Tolerance development
  - acute exposure, 265
  - analgesia, 265
  - chronic administration, 459
  - chronic exposure, 265
  - nicotine, 265
  - pentobarbital, 459
  - pigeon/rat comparisons, 459
  - restraint stress, 265
  - secobarbital, 459
- Toxicity study, 627
  - continuous administration
  - physostigmine
- Tricyclics, 807
  - $\beta$ -adrenoceptors
  - experimental diabetes
- Triglycerides, 75
  - cholesterol
  - cingulotomy
  - corticosterone
  - $\beta$ -endorphin
  - plasma
  - stress
- Tryptophan, 149
  - food selection
  - human studies, males
  
- Tyr-MIF-1, 129
  - ethanol
  - naloxone
  - strain differences
  - volitional drinking
  
- Urea, 699
  - acute administration
  - ammonium chloride
  - creatinine
  - thermoregulatory responses
- Urinary catecholamines, 287
  - fluorophotometric assay
  - high performance liquid chromatography with electrochemical detection
  
- Ventral tegmental area
  - behavioral activation, 255
  - brainstem, 547
  - cholinergic antagonists, 547
  - dopamine, 255
  - lateral hypothalamus, 547
  - neurokinin- $\alpha$
  - self-stimulation, 547
- Vocalization, 223
  - monkeys
  - opiate/adrenergic receptor blockade
- Volitional drinking, 129
  - ethanol
  - naloxone
  - strain differences
  - Tyr-MIF-1
  
- Water intake, 21
  - food intake
  - human satietin
  - route of administration
- Water maze performance, 487
  - food deprivation
  - food maze performance
  - plasma hormone levels
- Withdrawal
  - apomorphine, 163
  - ethanol, 163
  - lorazepam, 937
  - motility, 163
  - sensitization, 937
  - tolerance, 937
  
- Yawning, 717
  - apomorphine
  - genital grooming
  - luteinizing hormone releasing hormone
- Yohimbine, 321
  - antiserotonergic properties